Noun
an anti-TNF compound (trade name Remicade) consisting of an antibody directed against TNF; it is given intravenously at one-month to three-month intervals; used in treatment of regional enteritis and rheumatoid arthritis
a monoclonal antibody (trade name Remicade) used to treat Crohn's disease and rheumatoid arthritis; administered by infusion; use and dosage must be determined by a physician
Source: WordNetCases of transient visual loss have been reported during or within 2 hours of infusion of REMICADE. Source: Internet
Both HAQ-DI and SF-36 effects were maintained through Week 102. Approximately 80% of patients in all doses/schedules of REMICADE + MTX remained in the trial through 102 weeks. Source: Internet
In a randomized study evaluating REMICADE in moderate to severe (NYHA Class III/IV; left ≤35%), 150 patients were randomized to receive treatment with 3 infusions of REMICADE 10 mg/kg, 5 mg/kg, or placebo, at 0, 2, and 6 weeks. Source: Internet
Strong growth in sales of immunology drug Stelara more than offset the decline of Remicade, and sales of oncology drugs, led by Zytiga and Darzalex, grew 38.7% operationally. Source: Internet
Median follow-up was 24 weeks for the placebo group and 102 weeks for the REMICADE group. Source: Internet
More patients in the placebo group (12%) had readily apparent radiographic progression compared with the REMICADE group (3%). Source: Internet